The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)

Sonali M. Smith; Heiko Schöder; Jeffrey L. Johnson; Sin Ho Jung; Nancy L. Bartlett; Bruce D. Cheson

doi:10.3109/10428194.2012.744453

The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)

Sonali M. Smith, Heiko Schöder, Jeffrey L. Johnson, Sin Ho Jung, Nancy L. Bartlett, Bruce D. Cheson

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Relapsed Hodgkin lymphoma remains a clinical challenge, with few non-cytotoxic treatment options. CD80 is a surface antigen that normally functions as a co-stimulatory molecule but is aberrantly and uniformly expressed on Reed-Sternberg cells. Galiximab is a primatized monoclonal antibody against CD80, with a favorable toxicity profile demonstrated in other lymphomas. Cancer and Leukemia Group B (CALGB) 50602 (Alliance) tested single-agent galiximab in a highly refractory group of patients with Hodgkin lymphoma (median 3 prior regimens, 83% failing after prior stem cell transplant) to determine the efficacy. The overall response rate was 10.3% and the median progression-free survival was 1.6 months. Galiximab was well-tolerated, with minimal grade 3 or 4 toxicities. Despite this preclinical rationale, single-agent galiximab had limited activity in heavily pretreated Hodgkin lymphoma.

Original language	English
Pages (from-to)	1405-1410
Number of pages	6
Journal	Leukemia and Lymphoma
Volume	54
Issue number	7
DOIs	https://doi.org/10.3109/10428194.2012.744453
State	Published - Jul 2013

Keywords

CD80
Clinical trial
Galiximab
Hodgkin lymphoma

Access to Document

10.3109/10428194.2012.744453

Cite this

@article{d26fa93bd7354e3d885ff45ab6916efc,

title = "The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)",

abstract = "Relapsed Hodgkin lymphoma remains a clinical challenge, with few non-cytotoxic treatment options. CD80 is a surface antigen that normally functions as a co-stimulatory molecule but is aberrantly and uniformly expressed on Reed-Sternberg cells. Galiximab is a primatized monoclonal antibody against CD80, with a favorable toxicity profile demonstrated in other lymphomas. Cancer and Leukemia Group B (CALGB) 50602 (Alliance) tested single-agent galiximab in a highly refractory group of patients with Hodgkin lymphoma (median 3 prior regimens, 83% failing after prior stem cell transplant) to determine the efficacy. The overall response rate was 10.3% and the median progression-free survival was 1.6 months. Galiximab was well-tolerated, with minimal grade 3 or 4 toxicities. Despite this preclinical rationale, single-agent galiximab had limited activity in heavily pretreated Hodgkin lymphoma.",

keywords = "CD80, Clinical trial, Galiximab, Hodgkin lymphoma",

author = "Smith, {Sonali M.} and Heiko Sch{\"o}der and Johnson, {Jeffrey L.} and Jung, {Sin Ho} and Bartlett, {Nancy L.} and Cheson, {Bruce D.}",

note = "Funding Information: S.M.S. was supported by CA41287, H.S. was supported by CA77651, J.L.J. was supported by CA33601, N.L.B. was supported by CA77440 and B.D.C. was supported by CA77597. Funding Information: The research for CALGB 50602 (Alliance) was supported, in part, by grants from the National Cancer Institute (CA31946) to the Alliance for Clinical Trials in Oncology (Monica M. Bertagnolli, MD, Chair) and to the Alliance Statistics and Data Center (Daniel J. Sargent, PhD, CA33601). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.",

year = "2013",

month = jul,

doi = "10.3109/10428194.2012.744453",

language = "English",

volume = "54",

pages = "1405--1410",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

number = "7",

}

The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). / Smith, Sonali M.; Schöder, Heiko; Johnson, Jeffrey L. et al.
In: Leukemia and Lymphoma, Vol. 54, No. 7, 07.2013, p. 1405-1410.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma

T2 - Cancer and Leukemia Group B 50602 (Alliance)

AU - Smith, Sonali M.

AU - Schöder, Heiko

AU - Johnson, Jeffrey L.

AU - Jung, Sin Ho

AU - Bartlett, Nancy L.

AU - Cheson, Bruce D.

N1 - Funding Information: S.M.S. was supported by CA41287, H.S. was supported by CA77651, J.L.J. was supported by CA33601, N.L.B. was supported by CA77440 and B.D.C. was supported by CA77597. Funding Information: The research for CALGB 50602 (Alliance) was supported, in part, by grants from the National Cancer Institute (CA31946) to the Alliance for Clinical Trials in Oncology (Monica M. Bertagnolli, MD, Chair) and to the Alliance Statistics and Data Center (Daniel J. Sargent, PhD, CA33601). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.

PY - 2013/7

Y1 - 2013/7

N2 - Relapsed Hodgkin lymphoma remains a clinical challenge, with few non-cytotoxic treatment options. CD80 is a surface antigen that normally functions as a co-stimulatory molecule but is aberrantly and uniformly expressed on Reed-Sternberg cells. Galiximab is a primatized monoclonal antibody against CD80, with a favorable toxicity profile demonstrated in other lymphomas. Cancer and Leukemia Group B (CALGB) 50602 (Alliance) tested single-agent galiximab in a highly refractory group of patients with Hodgkin lymphoma (median 3 prior regimens, 83% failing after prior stem cell transplant) to determine the efficacy. The overall response rate was 10.3% and the median progression-free survival was 1.6 months. Galiximab was well-tolerated, with minimal grade 3 or 4 toxicities. Despite this preclinical rationale, single-agent galiximab had limited activity in heavily pretreated Hodgkin lymphoma.

AB - Relapsed Hodgkin lymphoma remains a clinical challenge, with few non-cytotoxic treatment options. CD80 is a surface antigen that normally functions as a co-stimulatory molecule but is aberrantly and uniformly expressed on Reed-Sternberg cells. Galiximab is a primatized monoclonal antibody against CD80, with a favorable toxicity profile demonstrated in other lymphomas. Cancer and Leukemia Group B (CALGB) 50602 (Alliance) tested single-agent galiximab in a highly refractory group of patients with Hodgkin lymphoma (median 3 prior regimens, 83% failing after prior stem cell transplant) to determine the efficacy. The overall response rate was 10.3% and the median progression-free survival was 1.6 months. Galiximab was well-tolerated, with minimal grade 3 or 4 toxicities. Despite this preclinical rationale, single-agent galiximab had limited activity in heavily pretreated Hodgkin lymphoma.

KW - CD80

KW - Clinical trial

KW - Galiximab

KW - Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84879358814&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.744453

DO - 10.3109/10428194.2012.744453

M3 - Article

C2 - 23194022

AN - SCOPUS:84879358814

SN - 1042-8194

VL - 54

SP - 1405

EP - 1410

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 7

ER -

The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this